Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.50 |
| ▸ | CPT2 | P23786 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473096 | 0.86 | CPT2 (0.43) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL1538353 | 0.82 | CPT2 (0.40) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL3993639 | 0.80 | HSPD1 (0.49) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL3800160 | 0.79 | HSPD1 (0.39) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL2557188 | 0.79 | HSPD1 (0.64) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL11584543 | 0.78 | ACLY (0.59) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL723184 | 0.76 | ACLY (0.57) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL11000169 | 0.73 | GRIK1 (0.36) | HSPD1BLMHSPE1ALDH1A1GRIK1 | |
| SCHEMBL28527107 | 0.73 | ACLY (0.53) | ACLYHSPD1BLMHSPE1CPT2 | |
| SCHEMBL4060328 | 0.73 | HSPD1 (0.62) | ACLYHSPD1BLMHSPE1CPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0865501-A1 | METHODS FOR REMOVING INTERFERENCES DUE TO ENDOGENOUS DEHYDROGENASES IN ENZYME ASSAYS | Dade Behring Marburg GmbH (DE) | 1998-09-23 | — | — | EP | claimed |
| WO-1997016562-A1 | METHODS FOR REMOVING INTERFERENCES DUE TO ENDOGENOUS DEHYDROGENASES IN ENZYME ASSAYS | DADE BEHRING MARBURG GMBH (DE) | 1997-05-09 | — | — | WO | claimed |
| US-5399556-A | Complex of ranitidine and a zinc citrate; gastrointestinal disorders, peptic ulcers | GLAXO GROUP LTD. (GB) | 1995-03-21 | — | — | US | claimed |
| US-5221688-A | Gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 1993-06-22 | — | — | US | claimed |
| EP-0454449-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | claimed |
| EP-0454469-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | claimed |
| EP-0445949-A1 | Pharmaceutical compositions comprising carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-09-11 | — | — | EP | claimed |
| JP-4225988-A | — | — | None | — | — | JP | disclosed |
| JP-4217676-A | — | — | None | — | — | JP | disclosed |
| EP-2831065-A1 | COMPOSITIONS CONTAINING TETRAHYDROFURFURYL AND/OR ALKYL-SUBSTITUTED TETRAHYDROFURFURYL ESTERS OF CITRIC ACID | 3M Innovative Properties Company (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2013148255-A1 | COMPOSITIONS CONTAINING TETRAHYDROFURFURYL AND/OR ALKYL-SUBSTITUTED TETRAHYDROFURFURYL ESTERS OF CITRIC ACID | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-03 | — | — | WO | disclosed |
| CN-102105132-A | Cosmetic use of microorganisms for treating oily skin | OREAL | 2011-06-22 | — | — | CN | disclosed |
| US-20030158118-A1 | Combination of cimetidine and cysteine derivatives for treating cancer | WEIDNER MORTEN SLOTH (DK) | 2003-08-21 | — | — | US | disclosed |
| EP-0454449-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0454449-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0454469-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0454469-A1 | Carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-10-30 | — | — | EP | disclosed |
| US-5049699-A | Citric acid, paraformaldehyde, acetic anhydride | HAARMANNS' REIMER CORP (US) | 1991-09-17 | — | — | US | disclosed |
| EP-0445949-A1 | Pharmaceutical compositions comprising carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-09-11 | — | — | EP | disclosed |
| EP-0445949-A1 | Pharmaceutical compositions comprising carboxylic acid derivatives | GLAXO GROUP LIMITED (GB) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158118-A1 | Combination of cimetidine and cysteine derivatives for treating cancer | MGMT, CMA1, CYSLTR2 | ACLY 2617/4885HSPD1 872/4885BLM 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.